FDMT: 4D Molecular Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 3 sales totaling $775K in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-16 | Bizily Scott | Officer | $21K | yes |
| 2026-10-05 | Kirn David | Officer | $750K | yes |
| 2026-10-05 | Kirn David | Officer | $4K | yes |
Institutional ownership (Q2 2026)
157 institutions reported holding $734.59M of 4D Molecular Therapeutics, Inc. on Form 13F (153 the quarter before). 27 opened a new position and 24 sold out. Shares held by institutions: +9%.
| Largest holders | Shares | Value |
|---|---|---|
| Jupiter Topco LLC | 5,746,289 | $76.47M |
| RA CAPITAL MANAGEMENT, L.P. | 5,049,779 | $67.16M |
| BlackRock, Inc. | 4,546,059 | $60.46M |
| GOLDMAN SACHS GROUP INC | 4,258,668 | $56.64M |
| NOVO HOLDINGS A/S | 3,249,178 | $43.21M |
| STATE STREET CORP | 2,911,109 | $38.72M |
| BVF INC/IL | 2,879,289 | $38.29M |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,249,203 | $29.91M |
| Trails Edge Capital Partners, LP | 2,227,917 | $29.63M |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,099,055 | $27.92M |
Clinical trial readouts
4 Phase 2 or 3 trials by 4D Molecular Therapeutics, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-03 (est.) | 4D-150 IVT | Neovascular (Wet) Age-Related Macular Degeneration | Phase 1/2 | 215 | Recruiting | NCT05197270 |
| 2027-06 (est.) | 4D-710 | Cystic Fibrosis Lung | Phase 2 | 30 | Recruiting | NCT05248230 |
| 2027-06 (est.) | 4D-150 IVT (3E10 vg/eye) | Macular Neovascularization Secondary to Age-Related Macular | Phase 3 | 480 | Enrollment complete | NCT06864988 |
| 2027-11 (est.) | 4D-150 IVT (3E10 vg/eye) | Neovascular Age-Related Macular Degeneration (nAMD) | Phase 3 | 480 | Recruiting | NCT07064759 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.